Back to today’s briefing

Story perspectives

New Imaging Tech and Drug Trial Target Obstructive Sleep Apnea

1/6/2025

24 5

Summary

Story summary

A groundbreaking imaging technique by SPIE harnesses swept-source optical coherence tomography (OCT) to unveil intricate 3D images of the airway, pinpointing blockages linked to obstructive sleep apnea (OSA). In a parallel advancement, Mineralys Therapeutics has secured FDA approval for a Phase 2 trial of lorundrostat, aiming to tackle OSA and hypertension, with trials kicking off in early 2025.

1 of 1

Story summary

A groundbreaking imaging technique by SPIE harnesses swept-source optical coherence tomography (OCT) to unveil intricate 3D images of the airway, pinpointing blockages linked to obstructive sleep apnea (OSA). In a parallel advancement, Mineralys Therapeutics has secured FDA approval for a Phase 2 trial of lorundrostat, aiming to tackle OSA and hypertension, with trials kicking off in early 2025.